Accuray stock analysis
Accuray (XEJ0) Stock Price & Analysis
XEJ0 Stock Chart & Stats
- Day’s Range
- EUR 0.09 - EUR 0.11
- 52-Week Range
- EUR 0.08 - EUR 1.04
- Previous Close
- EUR 0.10
- Volume
- N/A
- Average Volume (3M)
- 1,913
- Market Cap
- EUR 11.72M
- Enterprise Value
- EUR 130.51M
- Total Cash (Recent Filing)
- EUR 42.25M
- Total Debt (Recent Filing)
- EUR 135.97M
- Price to Earnings (P/E)
- ―
- Beta
- 0.84
- Next Earnings
- Jan 27, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Service Base
A growing installed base creates a durable service and maintenance revenue foundation that is less dependent on new system placements each quarter. More than $230 million of recurring annual revenue, supported by 90% contract capture, can improve visibility and customer lifetime economics over the next several years.
Cost Transformation And Service Margins
The lower structural cost base and stronger service margins indicate tangible operating improvements rather than relying only on revenue growth. If retained, these gains can improve earnings leverage as volumes recover, strengthen cash conversion, and provide greater flexibility to invest in commercial execution and product development.
Strategic Product Partnerships
The RaySearch partnership can strengthen Accuray's adaptive radiation therapy offering by combining complementary treatment delivery and planning capabilities. A broader integrated workflow may improve product differentiation, support future customer adoption, and reinforce the strategic relevance of Radixact and CyberKnife platforms.
Bears Say
Weak Product Demand
Weak product orders and a book-to-bill ratio below management's stated healthy level indicate that replacement and new-system demand is not currently replenishing shipments. Continued order weakness would pressure revenue, fixed-cost absorption, backlog conversion, and the ability to realize the benefits of the service platform.
Negative Cash Generation
Negative operating and free cash flow show that the business is not yet funding operations and investment internally. Persistent cash consumption can increase dependence on financing, limit investment in product and commercial initiatives, and reduce resilience if product volumes remain weak or working-capital needs rise.
High Leverage And Thin Equity Cushion
Debt materially exceeds the equity base, while negative returns on equity reflect ongoing losses and leave a thin capital cushion. This structure reduces financial flexibility, increases the importance of executing the transformation plan, and may constrain future capital allocation if operating performance remains inconsistent.
XEJ0 FAQ
What was Accuray’s price range in the past 12 months?
What is Accuray’s market cap?
When is Accuray’s upcoming earnings report date?
Is Accuray overvalued?
Does Accuray pay dividends?
What is Accuray’s EPS estimate?
How many shares outstanding does Accuray have?
Which hedge fund is a major shareholder of Accuray?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Accuray
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Stephen R. LaNeve
- Employees
- 809
- Website
- www.accuray.com
- Address
- 1240 Deming Way, Madison, WI, 53717-1954, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |

